Key drivers of this growth include the increasing number of decentralized clinical trials, the rising adoption ...

IQVIA Holdings on Tuesday narrowed its annual profit forecast, trimming the upper end of its outlook, as it expects cancellations of research contracts from pharmaceutical clients to persist into the ...

Get key takeaways from IQVIA’s record Q3 2025—strong bookings, free cash flow, AI momentum, and guidance reaffirmed.